特一药业：2025年全年净利润同比预增241.55%—339.13%

Core Viewpoint - The company, Te Yi Pharmaceutical, anticipates a significant increase in net profit for the year 2025, driven by marketing transformation, brand strategy advancement, and product recovery [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 70 million and 90 million yuan, representing a year-on-year increase of 241.55% to 339.13% [1] - The anticipated net profit after deducting non-recurring gains and losses is estimated to be between 67.5 million and 87.5 million yuan, reflecting a year-on-year growth of 263.83% to 371.64% [1] Business Strategy - The company's performance improvement is attributed to the recovery in core product sales and optimization of marketing channels [1] - Despite short-term impacts on profits due to investments in brand building, the overall operating profit has shown positive improvement, indicating successful outcomes from marketing reforms and brand development [1]